![](https://images.squarespace-cdn.com/content/v1/63762e5707c3be4b45d20cdc/274c49db-8883-44c1-81ac-1e35db0f215c/pexels-vidal-balielo-jr-3376799.jpg)
Your Gateway to Accelerated Medtech Clinical Study Results in Latin America
bioaccess® is the sole Medtech CRO in Latin America. We offer high-quality clinical research services, helping you advance your medical device from early studies to market.
bioaccess® Brings Certainty
We at bioaccess® are experts in delivering cost-effective, high-quality medical device CRO services in Latin America. We collaborate with Medtech startups seeking accelerated clinical study results.
With bioaccess® , you quickly and reliably receive regulatory approval, clinical research site activation, subject recruitment, and trial data.
We bring you certainty in:
✔️ Moving to the next phase (an FDA IDE pivotal study)
✔️ Raising funds
✔️ A successful exit
![](https://images.squarespace-cdn.com/content/v1/63762e5707c3be4b45d20cdc/174151c4-1b37-4d28-b7a0-5041190251ba/Sin+ti%CC%81tulo-3_Mesa+de+trabajo+1.jpg)
Advance Your Medical Device Sooner
Pilot Studies
Early-Feasibility Studies (EFS)
First-In-Human Studies (FIH)
Pivotal Studies
Post-Market Surveillance
Medtech clinical trials require high experience levels, specialized knowledge, and flexibility.
Our clinical research team consists of experts with over 15 years of experience, specializing in medical device research:
First-In-Human Studies (FIH)
Early Feasibility Studies (EFS)
Pilot Studies
Pivotal Studies
Post-Market Surveillance
bioaccess® has the expertise and customized approach you need to advance your medical device sooner.
Trusted By
Testimonials
Committed To Your Success
bioaccess® is a US-based CRO that bridges the gap between innovative Medtech companies and the untapped potential of conducting clinical research studies in Latin America.
Our team believes in the importance of your medical device and the benefit it could bring to people’s lives.
We are committed to helping you navigate the convoluted and uncertain developmental challenges of being an early-stage startup. Our priority is bringing you fast, cost-effective, and high-quality clinical data.